638 results on '"Cutillas, Pedro R."'
Search Results
2. Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
3. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
4. Microtubule-associated proteins MAP7 and MAP7D1 promote DNA double-strand break repair in the G1 cell cycle phase
5. Causal Role for Neutrophil Elastase in Thoracic Aortic Dissection in Mice
6. Maternal Immune Activation imprints translational dysregulation and differential MAP2 phosphorylation in descendant neural stem cells
7. Supplementary Figure 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
8. Supplementary Figure 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
9. TABLE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
10. Supplementary Figure 8 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
11. Data from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
12. FIGURE 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
13. Supplementary Figure 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
14. FIGURE 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
15. FIGURE 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
16. Supplementary Figure 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
17. Supplementary Figure 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
18. Supplementary Figure 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
19. FIGURE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
20. FIGURE 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
21. FIGURE 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
22. Supplementary Figure 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
23. TABLE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
24. FIGURE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
25. Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine
26. Comparison of multiple modalities for drug response prediction with learning curves using neural networks and XGBoost
27. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans
28. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs
29. Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
30. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
31. Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring
32. S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
33. Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer
34. Community detection in empirical kinase networks identifies new potential members of signalling pathways
35. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
36. Cancer associated fibroblast FAK regulates malignant cell metabolism
37. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells
38. Abstract 5841: Exploring the role of versican in immune exclusion within triple negative breast cancer
39. Supplementary Tables 10 - 14 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
40. Figure S2 from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
41. Supplementary Tables 4 - 9 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
42. Table S3 from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
43. Data from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
44. Data from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
45. Supplementary Tables 1 - 3 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
46. Supplementary Tables 15 - 25 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
47. Figures S1 - S6 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
48. Table S1 S2 S3 legend from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
49. Data from Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets
50. Supplementary Figures and Tables from Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.